HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

Ana Marcu 1,2, Leon Bichmann 1,3 Leon Kuchenbecker 3, Daniel Johannes Kowalewski 1, Lena Katharina Freudemann 1,2,4 Linus Backert 1,3 Lena Mühlenbruch 1,2,4 András Szolek 3, Maren Lübke 1,2 Philipp Wagner 1,5 Tobias Engler 5, Sabine Matovina 5, Jian Wang 6, Mathias Hauri-Hohl 7, Roland Martin 6, Konstantina Kapolou 8, Juliane Sarah Walz 1,2,9,10 Julia Velz 8, Holger Moch 11, Luca Regli 8, Manuela Silginer 12, Michael Weller 12, Markus W. Löfler 1,2,3,4,14 Florian Erhard 15, Andreas Schlosser 16, Oliver Kohlbacher 3,4,17,18,19,20,21 Stefan Stevanović 1,2,4 Hans-Georg Rammensee 1,2,4 Marian Christoph Neidert 8,22,23

To cite: Marcu A, Bichmann L, Kuchenbecker L, et al. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2021;9:e002071. doi:10.1136/jitc-2020-002071

ABSTRACT

Background The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies against cancer. Due to the poor availability of benign tissues, if available, normal tissue adjacent to the tumor has been used as a benign surrogate when defining tumor-associated antigens. However, this comparison has proven to be insufficient and even resulted in lethal outcomes. In order to match the tumor immunopeptidome with an equivalent counterpart, we created the HLA Ligand Atlas, the first extensive collection of paired HLA-I and HLA-II immunopeptidomes from 227 benign human tissue samples. This dataset facilitates a balanced comparison between tumor and benign tissues on HLA ligand level.

Methods Human tissue samples were obtained from 16 subjects at autopsy, five thymus samples and two ovary samples originating from living donors. HLA ligands were isolated via immunoaffinity purification and analyzed in over 1200 liquid chromatography mass spectrometry runs. Experimentally and computationally reproducible protocols were employed for data acquisition and processing.

Results The initial release covers 51 HLA-I and 86 HLA-II allotypes presenting 90,428 HLA-I and 142,625 HLA-II ligands. The HLA allotypes are representative for the world population. We observe that immunopeptidomes differ considerably between tissues and individuals on source protein and HLA-ligand level. Moreover, we discovered 1407 HLA-I ligands from non-canonical genomic regions. Such peptides were previously described in tumors, peripheral blood mononuclear cells (PBMCs), healthy lung tissues and cell lines. In a case study in glioblastoma, we show that potential off-target off-tumor adverse events in immunotherapy can be avoided by comparing tumor immunopeptidomes to the provided multi-tissue reference.

Conclusion Given that T-cell-based immunotherapies, such as CAR-T cells, affinity-enhanced T cell transfer, cancer vaccines and immune checkpoint inhibition, have significant side effects, the HLA Ligand Atlas is the first step toward defining tumor-associated targets with an improved safety profile. The resource provides insights into basic and applied immune-associated questions in the context of cancer immunotherapy, infection, transplantation, allergy and autoimmunity. It is publicly available and can be browsed in an easy-to-use web interface at https://hla-ligand-atlas.org.

INTRODUCTION

In the past two decades, sequencing the human genome (genomics), 1 2 transcriptome (transcriptomics) 3 4 and proteome (proteomics) 5-7 have been milestones that enable a multidimensional understanding of biological processes. In the context of the immune system, a subsequent omics layer can be defined as the human leucocyte antigen (HLA) ligandome or the immunopeptidome, comprising the entirety of HLA presented peptides. HLA molecules present peptides on the cell surface for recognition by T cells, which were generated and selected to distinguish self from foreign peptides. Despite HLA-I ligands originating primarily from intracellular proteins, the correlation with their precursors (mRNA transcripts and proteins) is poor, 9-11 limiting approaches based on in silico HLA-binding predictions in combination with transcriptomics and proteomics data alone. 12

The importance of investigating HLA ligandomes from human healthy and diseased tissues has been well recognized 13-15 to improve HLA-binding prediction algorithms 16-18 and immunogenicity prediction.
analysis, but also, to inform precision medicine. Direct evidence of naturally presented HLA ligands is required to prove visibility of target peptides to T cells. This is a challenge, for example, in the context of cancer immunotherapy approaches that aim to identify optimal tumor-specific HLA-presented antigens. While their discovery has been made possible by proteogenomics approaches, a major impediment still resides in the lack of benign tissues as a reference for the definition of tumor specificity of target peptides. Due to the scarce availability of benign human tissue ligandomes, common alternative strategies are based on transcriptomic datasets either from the same patient, or from multiple tissues extracted from publicly available repositories. Frequently, morphologically normal tissue adjacent to the tumor (normal tissues adjacent to tumor, NATs) is used as a control in cancer research. However, NATs have been shown to pose unique challenges, since they may be affected by disease and have been suggested to represent a unique intermediate state between healthy and malignant tissues, with a pan-cancer-induced inflammatory response. Additionally, for some malignancies, for example, of the brain, surgical resection of NATs is inadmissible. Even in cancers that allow for the extraction of NATs, it is still necessary to investigate the presence of potential tumor-associated antigens (TAA.s) on other tissues to anticipate on-target/off-tumor, systemic adverse events when administering immunotherapies to patients.

In this study, we, thus, employed tissues originating from research autopsies of subjects that have not been diagnosed with any malignancy and have deceased for other reasons, an approach previously described as a surrogate source of benign tissue. Although these tissues were affected by a range of non-malignant diseases, we designate them as benign to emphasize morphological normality and absence of malignancy. This definition of benign is in agreement with the definition used by the Genotype-Tissue Expression Consortium, which provides RNA sequencing data of benign tissues originating from autopsy specimens.

We performed a large-scale liquid chromatography mass spectrometry (LC-MS/MS)-based characterization of both HLA-I and HLA-II ligands providing data from benign human tissues obtained at autopsy. The HLA Ligand Atlas is a first draft of a pan-tissue immunopeptidomics reference library from benign tissues comprising for the first time 227 mostly paired HLA-I (198) and HLA-II (220) ligandomes from 29 different benign tissue types obtained from 21 human subjects. For the data analysis, we employed MHCquant, the first open-source customized computational tool for immunopeptidomics assays that provides database search, false discovery rate (FDR) scoring, label-free quantification and binding affinity predictions. In addition, we implemented a user-friendly, web-based interface to query and access the data at https://hla-ligand-atlas.org. Despite its unprecedented comprehensiveness, the HLA Ligand Atlas currently contains only a limited number of tissues and subjects. However, it has been designed as an open and extensible community resource and we invite other researchers to share additional data with us for inclusion in the database. Consistent quality control and data processing will ensure a high quality of the data.

RESULTS
The HLA Ligand Atlas: content and scope of the data resource
We describe the HLA Ligand Atlas, a dataset of matched HLA-I and HLA-II ligandomes of benign tissues. HLA-I and HLA-II ligands were isolated via immunoaffinity purification and identified by LC-MS/MS. HLA-binding prediction algorithms and an assessment of peptide length distributions were used to identify high-quality samples and only these were integrated into the dataset (online supplemental figure S1 describes the QC steps employed). Our online resource https://hla-ligand-atlas.org provides access to the dataset comprising HLA-I and HLA-II ligands (1% local peptide-level FDR), their source proteins, tissue and subject of origin, as well as all corresponding HLA allotypes classified as strong or weak binders through several user-friendly views (figure 1A and online supplemental figure S1). We have acquired HLA ligandome data from 29 distinct tissues obtained from 21 individuals, surmounting to 1274 LC-MS/MS runs from 225 mostly paired HLA-I (198) and HLA-II (220) samples (figure 1C and online supplemental table S1). The majority of samples was obtained from 14 subjects after autopsy, while 7 additional subjects contributed 5 thymus and 2 ovary samples after surgery. We performed a time series experiment on three benign samples, two ovaries and one liver (online supplemental figure S2) and observed no qualitative or quantitative degradation of the immunopeptidome for up to 72 hours after tissue removal, supporting the feasibility of employing autopsy tissue as input material for immunopeptidomics assays (online supplemental figure S2).

Overall, we identified 90,428 HLA-I and 142,625 HLA-II peptides with a local peptide-level FDR of 1% and estimated global peptide-level FDRs of 4.5% and 3.9% for HLA-I and HLA-II peptides, respectively. Identified peptides could be attributed to 51 HLA-I and 81 HLA-II allotypes.

Ultimately, this dataset increases the total number of registered HLA ligands from 440,231 to 467,319 for HLA-I and from 160,931 to 257,933 for HLA-II, as currently encompassed in SysteMHC and the immune epitope database (IEDB) figure 1B).

Moreover, we sought to approximate the worldwide HLA allele frequency of subjects included in the HLA Ligand Atlas. For this purpose, we computed population coverages using the IEDB Analysis Resources (http://tools.iedb.org/population/) (online supplement table S2). When considering at least one HLA allele match per individual, we observe an allele frequency of 95.1%, 73.6%, 93.0%, for HLA-A (n=16), HLA-B (n=21) and
**Figure 1** The HLA Ligand Atlas: content and scope of the data resource. (A) The high-throughput experimental and computational workflow steps used to analyze thousands of HLA-I and HLA-II peptides isolated from benign tissues. The resulting HLA-I and HLA-II immunopeptidomes are comprised in the searchable web resource: https://hla-ligand-atlas.org. See online supplemental figure S1 for details of the quality control workflow. See online supplemental figure S2 for proof of principle using autopsy tissues. (B) HLA-I and HLA-II peptides expand the known immunopeptidome as curated in the public repositories SysteMHC and IEDB. (C) Sample matrix: HLA-I- (blue triangles) and HLA-II samples (orange triangles) included in the HLA Ligand Atlas cover 29 different tissues obtained from 21 human subjects. See online supplemental table S1 for patient characteristics. (D) Position-wise coverage (%) of identified source proteins by HLA ligands binned into four groups: (1) exclusively covered by HLA-I peptides, (2) exclusively covered by HLA-II peptides and (3–4) covered by both and separated into higher position-wise coverage by either HLA-I or HLA-II peptides. HLA, human leucocyte antigen; IEDB, immune epitope database; LC-MS/MS, liquid chromatography mass spectrometry.
HLA-C (n=14) alleles, respectively. Within the same constraints, we observe allele frequencies of 78.8%, 99.5%, 98.2%, 92.3% for HLA-DPB1 (n=9), HLA-DQA1 (n=11), HLA-DQB1 (n=12) and DRB1 (n=19) alleles, respectively (online supplemental table S2).

Source proteins and HLA allotype coverage characteristics of HLA ligands

The HLA ligands in the dataset were identified based on 15,262 of the 20,365 proteins in Swiss-Prot, hereinafter referred to as source proteins. About half of these source proteins yield both HLA-I and HLA-II ligand identifications, 40% yield only HLA-I ligands and 8% only HLA-II ligands (figure 1D). We performed a gene ontology (GO) enrichment analysis of HLA-I and HLA-II exclusive source proteins, which corroborates the expected cellular compartments associated with the class-specific antigen presentation pathways, with HLA-I presenting primarily intracellular and HLA-II primarily extracellular proteins (figure 2F).

When looking at single amino acid residues across all source proteins (position-wise), 10% of the single residue positions are covered by HLAs ligands, a parameter that ranges from 0.02% to 1.15% for individual HLA allotypes (online supplemental figure S3). The mode of the overall peptide length distribution depicts the highest abundance of 9mers (60%) for HLA-I and of 15mers (18%) for HLA-II ligands (figure 2A). While 82% of the HLA-I ligands are predicted to bind to a subject’s HLA allotype, this holds true for only 62% of the HLA-II ligands. A major shortcoming of HLA-II binding prediction models appears to be a negative bias toward the tails of the observed peptide length distribution, in particular toward short peptides (figure 2A). The number of identified peptides that are predicted to bind to specific allotypes varies strongly between allotypes, with HLA-A*02:01, HLA-B*15:01, HLA-B*35:01, HLA-C*04:01 and most HLA-DRB1 allotypes being among the highly represented ones (figure 2B,C).

The interindividual heterogeneity outweighs similarities between tissue types

An unaddressed question, relevant for the discovery and administration of shared TAAs, is whether the similarity between tissue types outweighs that between individuals. We assessed the similarity of the immunopeptidome on both source protein (figure 2D,E) and HLA-ligand level (online supplemental figure S4C,D) between samples, as defined by subject-tissue combinations. For this purpose, we computed pairwise similarities between all samples as measured by the Jaccard similarity index and clustered the samples based on their similarity.

We observe that even on the source protein level there is a higher similarity between samples that originate from the same subject over samples that originate from the same tissues. Notably, while this effect is to some degree expected due to the allotype specific presentation behavior, it persists when only allele matched samples and peptides are taken into account (online supplemental figure S5). Prominent exceptions are the thymus samples, which form clusters within the HLA-I and HLA-II samples despite originating from different donors.

The immunopeptidome yield varies consistently across tissues

We observe a strong variance in the immunopeptidome yield, defined as the number of identified peptides per sample, across all tissues (figure 3A) and subjects (online supplemental figure S4A,B). Despite the interindividual (i.e. inter-allotype) variance, we can consistently differentiate between high-yielding and low-yielding tissues with respect to both HLA-I and HLA-II peptides (figure 3 and online supplemental figure S4A,B). The separation of tissues based on the immunopeptidome yield is not abrupt, but gradual. Low-yielding tissues include skin, aorta, brain and the gallbladder with a low number of both HLA-I and HLA-II presented peptides across all subjects. On the other hand, high-yielding tissues include thymus, lung, spleen, bone marrow and kidney (figure 3A). These tissues have well-characterized immune-related functions or are central components of the lymphatic system.

We employed a linear model to systematically evaluate the correlation between the median HLA-I/HLA-II immunopeptidome yield with RNA expression values (reads per kilobase per million - RPKM) of immune-related genes identified by targeted RNA sequencing from an external dataset35 (figure 3B and online supplemental figure S6). We observe a significant correlation between expression values of immune-related genes and HLA-I and HLA-II immunopeptidome yields (online supplemental figure S6). Among these, genes of the immunoproteasome correlate well with the number of HLA-I ligand identifications per tissue (R²=0.407, rho=0.671, p=0.001, figure 3B, left). Independent studies mapping the healthy human proteome confirm expression of the immunoproteasome in a wide range of tissues, including tissues for which no primary immunological function would be expected.67

HLA-II peptide yields correlate well with the expression of HLA-DRB1 genes (R²=0.244, rho=0.451, p=0.017, figure 3B, right). HLA-DR is well characterized due to the invariant α chain, and thus reduced complexity in the peptide binding groove. Through the high specificity of the L243 antibody for HLA-DR, and the presumably varying specificity of the second antibody Tu39 for different HLA-II allotypes, we cannot exclude a skewed identification in favor of HLA-DRB allotypes. However, higher expression values for HLA-DRB1 compared with other HLA-II allotypes have been described for example in earlier studies on gastric epithelium.33

Small subsets of source proteins are tissue exclusive

Previous studies characterizing the human transcriptome and proteome across tissues have shown varying degrees of tissue specificity for transcripts and proteins.34,35 In this context, we analyzed source proteins of the benign immunopeptidome as a whole and grouped all samples by
**Figure 2** (Continued)
tissue of origin. We observe a particularly small number of HLA-I (ranging from 5 in mamma to 674 in thymus), and HLA-II (ranging from 8 in ovary to 564 in thymus) source proteins identified exclusively in one tissue (figure 4A,B and online supplemental table S5). Concordantly, only small numbers of tissue-exclusive protein identifications have been observed in human tissue-wide proteomics studies.Only recently, the systematic, quantitative analysis of the human proteome and transcriptome in multiple tissues has revealed that differences between tissues are rather quantitative than defined by the presence or absence of certain proteins.

To determine whether tissue-specific biology is conserved between the transcriptome and immunopeptidome, we compared tissue-enriched gene sets from the GTEx repository with tissue-exclusive HLA-I and HLA-II source proteins (figure 4A,B, left). We observe that tissue-specific biology is represented by HLA-I and HLA-II source proteins through an enrichment with upregulated transcripts in the respective tissue.

We additionally observed that tissue-specific traits are recapitulated by GO term enrichment of biological processes (figure 4A,B, right). Enriched GO terms reveal tissue-specific biological functions such as ‘adaptive immune response’ in the thymus or ‘behavior’ in the brain. However, clear associations between enriched gene sets and HLA-I and HLA-II source proteins are less evident in tissues such as spleen or testis, despite the disparity of tissue-exclusive HLA-I source protein identifications, accounting for only 23 in testis, while spleen yields 308.

Overall, tissue-specific traits are more evident for HLA-I than for HLA-II source proteins when assessing the correlation between tissue-exclusive source proteins with GTEx-enriched transcripts and function-specific GO terms. HLA-II source proteins are represented by more general GO terms, which still reflect distinct biological processes characteristic for the respective tissue.

Cryptic peptides are part of the benign immunopeptidome

Recently, cryptic HLA peptides came into focus as a new potential source of TAAs. Cryptic peptides originate from non-coding regions, that is, 5′- and 3′-untranslated region (UTR), non-coding RNAs (ncRNA), intronic and intergenic regions, or from shifted reading frames in annotated protein coding regions (off-frame). Ribosome profiling and immunopeptidomics studies confirm their translation and presentation on HLA-I molecules.

So far, cryptic peptides have predominantly been characterized in tumors, while their presentation in benign tissues remains poorly charted. We analyzed the HLA-I-restricted LC-MS/MS data of the HLA Ligand Atlas with Peptide-PRISM and identified 1407 cryptic peptides, including the peptide SVASPVTLGK that was classified as a TAA in lung cancer tissue in a previously published study (figure 5F and online supplemental table S3). This peptide was identified in the HLA Ligand Atlas in five different subjects in lung and liver tissues. We find that 47% of cryptic peptides were identified in more than one subject (online supplemental table S3). Both cryptic and conventional peptides share similar physicochemical properties. Their predicted chromatographic retention time correlates with their experimentally observed retention time equally well as for conventional peptides (figure 5D). The identified cryptic peptides predominantly originate from 5′-UTRs (figure 5C), which is in accordance with previous studies.

Overall, HLA allotypes show different presentation propensities of cryptic peptides, when related to cryptic and canonical peptides, with HLA-A*03:01 covering the largest fraction of all identified cryptic peptides, followed by HLA-A*68:01 and HLA-B*07:02, as previously observed (figure 5B).

We selected 36 top-ranking (1% FDR) cryptic peptides, shared among subjects for spectral validation by experimental comparison with the corresponding isotopically-labeled synthetic peptide (online supplemental table S3). We were able to confirm the correct identification of selected cryptic HLA-I ligands by comparing the pairwise similarity (spectral angle) between experimental and synthetic peptides against a random distribution (figure 5E) as well as through individual inspection (online supplemental figure S7). In summary, we can show that cryptic peptides are not per-se tumor-specific, although their frequency might be reduced in benign tissues.

HLA Ligand Atlas data enables prioritization of TAAs

On-target/off-tumor adverse events in a clinical immunotherapeutic setting can have fatal consequences. To minimize the risk of on-target/off-tumor adverse events, multi-tissue immunopeptidomics reference libraries from benign tissues are required to identify TAAs. Here, we...
propose the implementation of the HLA Ligand Atlas as a reference library of benign multi-tissue immunopeptidomes for comparative profiling with tumor immunopeptidomes for the discovery of actionable TAAs. As a case study, we selected three glioblastoma tumor samples from different individuals and analyzed their immunopeptidomes. We comparatively profiled the 11,784 HLA-I ligands identified in the glioblastoma samples against the benign dataset encompassed in the HLA Ligand Atlas (figure 6A,B). The majority of HLA ligands is shared between both tumor and benign tissues, with 5185 HLA-I TAAs and 3243 HLA-II TAAs being unique to glioblastoma (online supplemental table S4). When assessing their presentation frequency, 690 HLA-I TAAs are found on two glioblastoma samples, while 4494 are patient-individual. In the case of HLA-II TAAs, 42 are shared between two glioblastoma patients, and 3201 are patient individual. No identified HLA-I or HLA-II ligands were common to all three glioblastoma patients.

Moreover, we investigated the presentation of cancer testis antigens (CTAs) by HLA-I and HLA-II molecules on benign tissues. CTAs are immunogenic proteins preferentially expressed in normal gametogenic tissues and different types of tumors. We compiled a list of 422
published CTAs from the curated CT database and a recent publication aiming to identify CTAs from transcriptomics datasets. Of 422 published CTAs, 49 CTAs were presented on either HLA-I or HLA-II molecules and 10 CTAs on both HLA-I and HLA-II molecules in the HLA Ligand Atlas, provided that respective source proteins were identified with at least two HLA ligands (figure 6B and online supplemental table S4). CTAs, such as CTAGE5, KIA0100 and SPAG9, were presented in numerous benign samples with HLA-I and HLA-II ligands (figure 6B and online supplemental table S4). Furthermore, the CTA KIA1210 was only identified in the benign dataset on testis in accordance to its CTA status. Similarly, we queried all glioblastoma source proteins against the selected 422 CTAs and found three CTAs (two HLA-I and one HLA-II) exclusively presented in glioblastoma and
not in our benign dataset, indicating promising targets against this tumor entity.

**HLA ligands form hotspots in source proteins**

When looking at the position-wise coverage profiles of individual source proteins across all HLA allotypes, we observe that HLA ligands seem to emerge from spatially clustered hotspot regions while other areas of the source protein do not contribute any HLA ligands (figure 6C, left). It has been shown previously that this clustering effect cannot be explained by the occurrence of HLA binding motifs as incorporated in epitope prediction tools. The hotspot locations often coincide between HLA-I and HLA-II ligands, however, we did not perform a large-scale statistical analysis to validate this class linkage effect. In the case of HLA-II, the clustering effect has to be distinguished from the co-occurrence of HLA-II ligand length variants, which leads to a large number of distinct peptides covering the same source protein position.
A TAAS IN Glioblastoma (GBM)

B OVERLAP OF CTAs WITH HLA SOURCE PROTEINS

C PEPTIDES FORM HOTSPOTS IN SOURCE PROTEINS

Figure 6 (Continued)
**DISCUSSION**

The HLA Ligand Atlas provides for the first time a comprehensive collection of benign human HLA-I and HLA-II immunopeptidomes. Both the experimental and computational workflows were designed in a standardized and reproducible fashion. The data resource enables further data-driven research to improve our mechanistic understanding of antigen presentation and will substantially enhance HLA binding prediction models. In addition, the analyses presented here already underline the individuality of HLA ligandomes, even beyond the rather well understood heterogeneity imposed by HLA allotypes. Our evaluation of pairwise sample similarity provides evidence that differences between individuals surpass differences between tissue types in the same individual for both the immunopeptidome and their source proteins even when samples are matched for HLA allotypes. On the proteome 144 and transcript levels,144 however, samples were previously shown to cluster by tissue type, rather than by individual. In line with this finding, a weak correlation between immunopeptidome yield and RNA expression values has been observed previously.10 11

It is evident that allotype-specific presentation by HLA is crucial to explain the different behavior on the level of proteomes and ligandomes. However, when comparing HLA-matched datasets, the clustering by individual is still evident and thus additional effects (eg, other—potentially unknown—steps in the HLA-I antigen processing pathway) could play an important role as well.

This high degree of individuality between immunopeptidomes has major repercussions for clinical applications in emerging fields such as immuno- oncology. Our findings indicate that the immunopeptidome adds an additional layer of complexity to the well-described genomic and transcriptomic tumor-heterogeneity. Successful induction of T-cell responses after peptide vaccination with neoantigens42 43 indicate that precision medicine will evolve to an increasingly individualized field, where treatment options will be tailored to the immunopeptidomic landscape of the tumor. Mapping the tumor HLA ligandome of an individual patient therefore needs to be paralleled by a broad and in-depth knowledge of its benign counterpart—the HLA Ligand Atlas is a first step in this direction.

An essential application of the HLA Ligand Atlas is the selection of candidate peptide targets for immunotherapy approaches. We propose to prioritize the large candidate pool of non-mutated tumor-associated targets by comparatively profiling immunopeptidomes of primary tumors and benign tissues, as provided by the HLA Ligand Atlas. This approach would complement current strategies based on transcriptomes of benign tissues as comprised for example in GTEx.3 4 The HLA Ligand Atlas represents a first draft of a tissue-wide immunopeptidomics map covering both HLA-I and HLA-II canonical peptides, but also HLA-I non-canonical peptides that can be employed as an orthogonal level of quality control when defining TAAs.

Advances in LC-MS/MS technology, data acquisition methods and computational tools are constantly improving the depth of coverage of immunopeptidomics experiments. Therefore, we encourage the reanalysis of the raw LC-MS/MS dataset with novel hypotheses and upcoming computational methods that will lead to additional insight. Overall, we anticipate that the number of charted human immunopeptidomes will increase,
similarly as the human genome and transcriptome were mapped across multiple individuals. By generating larger datasets from many human individuals, population-wide conclusions can be drawn, and immunopeptidome-wide studies will provide insight into disease-associated HLA alleles and peptides.\(^{14}\) The HLA Ligand Atlas strives to advance our understanding of fundamental aspects of immunology relating to autoimmunity, infection, transplantation, cancer immunotherapy and might provide a foundation for vaccine design. We hope that together with the scientific community we can expand the benign immunopeptidome to encompass more human subjects, tissues and HLA alleles.

**METHODS**

**Experimental model and subject details**

Human tissue samples were obtained post-mortem during autopsy performed for medical reasons at the University Hospital Zürich. None of the subjects included in this study was diagnosed with any malignant disease. Tissue samples were collected during autopsy, which was performed within 72 hours after death. Tissue annotation was performed by a board-certified pathologist. Tissue samples were immediately snap-frozen in liquid nitrogen.

Thymus samples were obtained from the University Children’s Hospital Zürich/ Switzerland. Thymus tissue was removed during heart surgery for other medical reasons.

Furthermore, two benign ovarian tissue samples were collected for the time series experiments (OVA-DN278 and OVA-DN281). Both patients were post-menopausal and had a bilateral ovarectomy for cystadenofibromas, which were diagnosed by histopathological examination of the specimen. The samples were obtained from a normal part of the ovary.

Finally, we included three primary glioblastoma tumor samples to illustrate a selection strategy for TAs. The primary glioblastoma tumor was analyzed for patients GBM616 and GBM654, whereas, a recurrent tumor was analyzed for GBM753.

**HLA typing**

Multiple HLA typing approaches were performed for the different sources of patient material.

Autopsy subject AUT-DN08, AUT-DN16, and two benign ovary samples (OVA-DN278 and OVA-DN281) were typed at the Department of Transfusion Medicine of the University Hospital of Tübingen. High-resolution HLA typing was performed by next-generation sequencing on a GS Junior Sequencer using the GS GType HLA Primer Sets (both Roche, Basel, Switzerland). HLA typing was successful for HLA-A, -B, and -C alleles. However, HLA-II typing was only reliable for the HLA-DR locus, and incomplete for the HLA-DP and -DQ loci.

Therefore, we performed exome sequencing of lung tissue for remaining autopsy subjects. The HLA-I and HLA-II alleles were identified from the exome sequencing data using an improved version of OptiType\(^{14}\) available online at https://github.com/FRED-2/OptiType (tagged hla-ligand-atlas).

Finally, sequence-based typing was performed for the five thymus samples and the three glioblastoma samples, by sequencing exons 1–8 for HLA-I alleles and exons 2–6 for HLA-II alleles (Histogenetics, Ossining, New York, USA).

The subject characteristics are summarized in online supplemental table S1 encompassing information on sex, age, the number of collected tissues and HLA-I and HLA-II alleles.

**HLA immunoaffinity purification**

HLA-I and HLA-II molecules were isolated from snap-frozen tissue using standard immunoaffinity chromatography. The antibodies employed were the pan-HLA-I-specific antibody W6/32,\(^{45}\) and the HLA-DR-specific antibody L243,\(^{46}\) produced in house (University of Tübingen, Department of Immunology) from HB-95, and HB-55 cells (ATCC, Manassas, Virginia, USA), respectively. Furthermore, the pan-HLA-II-specific antibody Tü39 was employed and produced in house from a hybridoma clone as previously described.\(^{47}\) The antibodies were cross-linked to CNBr-activated sepharose (Sigma-Aldrich, St. Louis, Missouri, USA) at a ratio of 40 mg sepharose to 1 mg antibody for 1 g tissue with 0.5 M NaCl, 0.1 M NaHCO\(_3\), at pH 8.3. Free activated CNBr reaction sites were blocked with 0.2 M glycine.

For the purification of HLA-peptide complexes, tissue was minced with a scalpel and further homogenized with the Potter-Elvehjem instrument (VWR, Darmstadt, Germany). The amount of tissue employed for each purification is documented in online supplemental table S1. This information is not available for seven tissues, annotated as n.d. in said table. Tissue homogenization was performed in lysis buffer consisting of CHAPS (Panreac AppliChem, Darmstadt, Germany) and one Complete protease inhibitor cocktail tablet (Roche) in PBS. Thereafter, the lysate was sonicated and cleared by centrifugation for 45 min at 4000 rpm, interspaced by 1 hour incubation periods on a shaker at 4°C. Lysates were further cleared by sterile filtration employing a 5 µm filter unit (Merck Millipore, Darmstadt, Germany). The first column contained 1 mg of W6/32 antibody coupled to sepharose, whereas the second column contained equal amounts of Tü39 and L243 antibody coupled to sepharose. Finally, the lysates were passed through two columns cyclically overnight at 4°C. Affinity columns were then washed for 30 min with PBS and for 1 hour with water. Elution of peptides was achieved by incubating four times successively with 100–200 µL 0.2% trifluoroacetic acid (TFA) on a shaker. All eluted fractions were subsequently pooled. Peptides were separated from the HLA molecule remnants by ultrafiltration employing 3 kDa and 10 kDa Amicon filter units (Merck Millipore) for HLA-I and HLA-II, respectively. The eluate volume was then reduced to approximately 50 µL by lyophilization or vacuum centrifugation.
Finally, the reduced peptide solution was purified five times using ZipTip pipette tips with C18 resin and 0.6μL bed volume (Merck,) and eluted in 32.5% acetonitrile (ACN)/0.2% TFA. Each peptide eluate was purified by loading it five times onto the same ZipTip pipette tip. The tip was passed sequentially by pipetting ten times up and down through 32.5% ACN/0.2% TFA for purification, 0.1% TFA for equilibration, the sample for binding the peptides, 0.1% TFA for desalting and 32.5% ACN/0.2% TFA for elution. This entire sequence was repeated five times using the same ZipTip pipette tip. The purified peptide solution was concentrated by vacuum centrifugation and supplemented with 1% ACN/0.05% TFA and stored at −80°C until LC-MS/MS analysis.

**Time series experiments**

We performed time series experiments to assess the suitability of tissues obtained from autopsies as a source of human tissues for the characterization of the benign immunopeptidome. We evaluated the degradation profile of the immunopeptidome, when tissues were stored at 4°C for up to 72 hours after tissue removal, to mimic the conditions at autopsy. The time series experiment was repeated in three benign tissues from different individuals: one benign liver obtained at autopsy (AUT-DN16 Liver), and two benign ovaries removed surgically (OVA-DN278 and OVA-DN281). The tissues were extracted and incubated at 4°C until the defined time point and flash-frozen in liquid nitrogen until HLA ligand extraction. As more tissue was available form AUT-DN16 Liver, tissue samples were frozen after 8 hours, 16 hours, 24 hours, 48 hours and 72 hours. Due to the limited sample amount obtained from OVA-DN278 and OVA-DN281, only three time points could be accounted for: 0 hours, 24 hours and 72 hours. The HLA immunofinity purification was performed as mentioned, with the exception that mass to volume ratio in ovary samples was adjusted to the lowest mass across all time points before loading onto sepharose columns.

**Mass spectrometric data acquisition**

HLA ligand characterization was performed on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, California, USA) equipped with a Nanospray Flex Ion Source (Thermo Fisher Scientific) coupled to an Ultimate 3000 RSLC Nano UHPLC System (Thermo Fisher Scientific). Peptide samples were loaded with 1% ACN/0.05% TFA on a 75µm × 2cm Acclaim PepMap 100 C18 Nanotrap column (Thermo Fisher Scientific) at a flow rate of 4µL/min for 10min. Separation was performed on a 50µm × 25 cm PepMap RSLC C18 (Thermo Fisher Scientific) column, with a particle size of 2µm. Samples were eluted with a linear gradient from 3% to 40% solvent B (80%/0.15% FA in water) at a flow rate of 0.3µL/min over 90min. The column was subsequently washed by increasing to 95% B within 1min, and maintaining the gradient for 5min, followed by reduction to 3% B and equilibration for 23min.

Data acquisition was performed as technical triplicates in data-dependent mode, with customized top speed (3s) methods for HLA-I and HLA-II-eluted peptides. HLA-I peptides have a length of 8–12 amino acids,48 49 therefore, the scan range was restricted to 400–650 m/z and charge states of 2–3. MS1 and MS2 spectra were detected in the Orbitrap with a resolution of 120,000 and 30,000, respectively. Furthermore, we set the automatic gain control (AGC) targets to 1.5*10^5 and 7.0*10^4 and the maximum injection time to 50 ms and 150 ms for MS1 and MS2, respectively. The dynamic exclusion was set to 7s. Peptides were fragmented with collision-induced dissociation while the collision energy was set to 35%. HLA-II peptides have a length of 8–25 amino acids,49 50 thus, the scan range was set to 400–1000 m/z and the charge states were restricted to 2–5. Readout for both MS1 and MS2 were performed in the Orbitrap with the same resolution and maximum injection times as for HLA-I peptides. The dynamic exclusion was set to 10s and AGC values employed were 5.0*10^5 and 7.0*10^4 for MS1 and MS2, respectively. Higher-energy collisional dissociation fragmentation with 30% collision energy was employed for HLA-II peptides.

The LC-MS/MS immunopeptidomics data comprised in the HLA Ligand Atlas has been deposited to the ProteomeXchange Consortium via the PRIDE53 partner repository.

**Database search with MHCquant**

MS data obtained from HLA ligand extracts was analyzed using the nf-core32 containerized, computational pipeline MHCquant36 (release V.1.5.1 - https://www.openms.de/mhcquant/) with default settings. The workflow comprises tools to analyze LC-MS/MS data of the open-source software library OpenMS (V.2.5).33 Identification and post-scoring were performed using the OpenMS adapters to Comet 2016.01 rev.54 and Percolator V.3.45 at a local peptide-level FDR threshold of 1% among the technical replicates per sample. Subsequently, we estimated the global peptide-level FDR by dividing the sum of expected false positive identifications from each sample (1% peptide level FDR) by the total number of identified peptides in the entire dataset (HLA-I: 4.5% FDR, HLA-II: 3.9% FDR).36 57 The human reference proteome (Swiss-Prot, Proteome ID UP000005640, 20,365 protein sequences) was used as a database reference. Database search was performed without enzymatic restriction, with methionine oxidation as the only variable modification. MHCquant settings for high-resolution instruments involving a precursor mass tolerance of 5 ppm and a fragment bin tolerance of 0.02 Da were applied. The peptide length restriction, digest mass and charge state range were set to 8–12 amino acids, 800–2500 Da and 2–3 for HLA-I and 8–25 amino acids, 800–5000 Da and 2–5 for HLA-II, respectively. No protein inference was performed, however, all proteins that contain a given peptide were annotated as peptide source proteins.
HLA binding prediction

Peptide binding predictions were computed based on the subject’s HLA alleles. For HLA-I ligand extracts, we employed SYFPEITHI\textsuperscript{58} and NetMHICpan-4.1\textsuperscript{59} in ligand mode (default). The SYFPEITHI score $s_{\text{SYF}}$ was computed by dividing the sum of amino acid-specific values for each position in the tested peptide by the maximally attainable score for the respective HLA allotypes.\textsuperscript{60} HLA-II ligand extracts were annotated with NetMHCIIPan-4.0\textsuperscript{18} and MixMHIC2pred\textsuperscript{17} using the default settings.

Peptides were categorized as strong binders against a given HLA allotype if any tool reported it as such (netMHCIpan-4.1 $s_{\text{rank}} \leq 0.5$, netMHCIIPan-4.0 $s_{\text{rank}} \leq 1.0$, MixMHIC2pred $s_{\text{rank}} \leq 1.0$, where $s_{\text{rank}}$ is the reported percentile rank score). Peptides were otherwise reported as weak binders if any of the tools reported it as such (netMHCIpan-4.1 $s_{\text{rank}} \leq 2.0$, netMHCIIPan-4.0 $s_{\text{rank}} \leq 5.0$, MixMHIC2pred $s_{\text{rank}} \leq 5.0$, SYFPEITHI $s_{\text{SYF}} \geq 0.5$). All peptide-HLA allotype associations within these limits were included in the dataset, that is, a single peptide sequence can be reported as a binder against multiple allotypes of the same donor. Throughout this article, unless allele associations are specified, all peptides including those classified as non-binders against any subject’s allotype were included in the analysis.

Binding prediction and length distribution-based quality control

We defined the fraction of predicted binders of a sample as the ratio of predicted binders divided by the total number of peptide identifications. Technical replicates with a fraction of predicted binders lower than 50% for HLA-I and lower than 10% for HLA-II ligand extracts were excluded from the dataset. Furthermore, individual replicates were removed from the dataset if the mode of the length distribution differed from nine amino acids for HLA-I and was not in the interval [12, 18] for HLA-II (see online supplemental file 1).

Quantitative time series analysis

Database search of LC-MS/MS data from the three time series experiments was performed with MHCQuant V.1.5.1 as previously described.\textsuperscript{20} Identifications were matched between runs\textsuperscript{61} based on retention time alignment and targeted feature extraction\textsuperscript{62} to integrate respective MS1 areas for all time points and technical replicates.

MS1 areas $x$ were normalized to z-scores (standard scores) $z$ per MS run by subtracting the mean and dividing by SD:

$$z = \frac{(x-\mu)}{\sigma}$$

The trajectory of scaled MS1 areas was clustered by k-means unsupervised clustering with six seeds using the tslearn (V.0.3.1) python package. All trajectories are related to the first time point by subtracting its median z-score from all other timepoints in the respective analysis.

Comparison of the HLA-Ligand-Atlas database with IEDB and SysteMHC

All peptides contained in the HLA Ligand Atlas database were compared with peptides listed in the IEDB and SysteMHC databases for HLA-I and HLA-II ligands separately. The list of peptides stored in the IEDB was obtained by downloading the file ‘epitope_full_v3.zip’ from the ‘Database Export’ page. The obtained table was subsequently filtered for positive MS assays, linear peptides and human origin. Peptides with modifications were removed. Peptides stored in the SysteMHC database were obtained by downloading the file ‘180409_master_final.tgz’ from ‘Builds_for_download’ page. The obtained table was subsequently filtered for human as organism.

GO-term enrichment

GO term enrichment analyses were performed using the Panther\textsuperscript{63} ‘statistical overrepresentation test’ (Release 2020-07-28) based on the 2020-10-09 GO Ontology database release (DOI: 10.5281/zenodo.4081749). Gene identifiers of source proteins presented exclusively by either HLA-I or HLA-II allotypes were queried against the ‘GO cellular component complete’ database using the default ‘Homo sapiens genes’ reference list. GO terms were sorted by Fisher’s exact raw p value, and top 10 scoring terms reported as overrepresented and their corresponding p values were selected for illustration.

Tissue-specific source proteins were defined as HLA-I or HLA-II source proteins identified exclusively in one tissue across all subjects (online supplemental table S5). Gene identifiers of tissue-specific HLA-I and HLA-II source proteins were queried against the ‘GO biological process complete’ database, with the only difference that only the top five scoring terms reported as overrepresented were selected for illustration.

Tissue-specific gene set enrichment

Analogously to the GO-term enrichment, tissue-specific HLA-I and HLA-II source proteins were separately queried against the GTEx database for gene set enrichment analysis. Gene sets with upregulated gene expression profiles per tissue ‘GTEx_Tissue_Sample_Gene_Expression_Profiles_up’ were retrieved using the gseapy implementation (V.0.9.15, 2019-08-07) through the enrichr API. All tissues covered in the HLA Ligand Atlas were matched and compared against all tissues in the GTEx database that co-occur in the HLA Ligand Atlas. Fisher’s exact raw p values for the enrichment were computed for each pairwise comparison.

HLA-I and HLA-II peptide yield correlation to expression of immune-related genes

We computed a linear model to compare the median HLA-I peptide yields per tissue with gene expression values (RPKM) of the following genes involved in the HLA-I presentation pathway: HLA-A, HLA-B, HLA-C, immunoproteasome, constitutive proteasome, TAP1 and TAP2. Median HLA-II peptide yields per tissue were

Marcu A, et al. J Immunother Cancer 2021;9:e002071. doi:10.1136/jitc-2020-002071
correlated to genes involved in the HLA-II presentation pathway: HLA-DRB1, HLA-DRA, HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1. The corresponding gene expression values were taken from a previously published study.32

An ordinary least squares linear model correlating gene expression and \( \log_{10} \) median HLA-I and HLA-II peptide yields was computed using R (V.3.5) and the corresponding stats (V.3.5) package reporting \( R^2, \) F-statistic p value and spearman rho. The cross-correlation between all immune-related genes and their individual linear models (figure 3 and online supplemental figure S6) was computed using R (V.3.5) and the corresponding packages corrplot (V.0.84) and ggplot2 (V.3.2.1). As the expression levels of the investigated genes are highly covariant (online supplemental figure S6A,C), the regression would be overfitting when correlating peptide yields to multiple genes involved in the antigen presentation pathway, thus the analysis was limited to a single gene at a time.

**Computation of Jaccard coefficients between samples**

We investigated the similarity of immunopeptidomes between tissues and subjects by pairwise comparison of all samples in the HLA Ligand Atlas. Comparisons were performed both on HLA-I and HLA-II level as well as on peptide and source protein level. The Jaccard index was calculated by dividing the set intersection by the set union for all pairwise comparisons:

\[
j = \frac{A \cap B}{A \cup B}
\]

**Identification of cryptic peptides with Peptide-PRISM**

Identification of cryptic HLA-I peptides from HLA-I LC-MS/MS data was performed as recently described in detail.37 Briefly, de novo peptide sequencing was performed with PEAKS Studio X64 65 (Bioinformatics Solutions, Canada). Top 10 sequence candidates were exported for each fragment ion spectrum. Database matching of all sequence candidates and stratified FDR-filtering was performed with Peptide-PRISM using the six-frame translation of the HG38 and the three-frame translation of the human transcriptome (Ensembl 90). Matched peptides were filtered to 10% FDR and peptides were predicted as binder to the corresponding HLA alleles by NetMHCPan-4.0.36 Peptide-PRISM is a hybrid approach for the identification of HLA-I peptides that combines de novo peptide sequencing with highly efficient string search. Peptide-PRISM facilitates fast and sensitive identification of HLA-I peptides in extremely large databases that cannot be searched with classical search engines. Basically, Peptide-PRISM matches the peptide sequences of the top 10 de novo candidates of all fragment ion spectra against the three-frame translated human transcriptome and the six-frame translated human genome. Stringent FDR-decoy approach in combination with mixture modeling for deconvoluting the overall de novo score distribution into components of false and true identifications. Since correct FDR filtering requires different de novo score thresholds for peptides of different length and for peptides from different categories (CDS, 5’-UTR, 3’-UTR, out-of-frame, ncRNA, intronic, intergenic), FDR filtering is performed separately for these categories (for more details see37). Thus, Peptide-PRISM facilitates the reliable and sensitive identification of cryptic HLA-I peptides. Due to the overall low relative abundance of cryptic peptides (~1%) in benign tissue it was not possible to reveal data about the tissue prevalence of cryptic HLA-I peptides.

**Retention time model for cryptic peptide validation**

Retention time predictions were carried out using the OpenMS (V.2.5.0) RTModel based on oligo-kernel v-support vector regression (\( v=0.5, p=0.1, c=1, \) border_length=22, kmer_length=1, \( \Sigma=5 \)).66 The model was trained on all peptide identifications of canonical peptides identified with MHCquant and applied to all cryptic peptide identifications resulting from Peptide-PRISM. Predictions were evaluated by applying a linear least square fit to compute the 99% prediction interval around the predicted versus measured retention times using the statsmodels (V.0.11) function wls_prediction_std.

**Synthesis of isotope-labeled peptides**

Peptides were synthesized using the Liberty Blue Automated Peptide Synthesizer (CEM) following the standard 9-fluorenylmethyl-oxycarbonyl/tert-butyl strategy. After removal from the resin by treatment with TFA/ triisopropylsilane/water (95/2.5/2.5 by vol.) for 1 hour, peptides were precipitated from diethyl ether, washed three times with diethyl ether and resuspended in water prior to lyophilization. Purity and identity of the synthesis products were determined by C18-HPLC (Thermo Fisher Scientific, Darmstadt, Germany) and LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific), respectively. These peptides were synthesized in house with an isotopic label, in order to avoid cross-contamination of native peptide eluates isolated in house as well as the synthesized cryptic peptides of interest.

**Spectrum validation**

We selected 36 cryptic peptides, identified with an FDR of 1% for spectral validation with isotope-labeled synthetic peptides. Selected peptides were strong binders to the corresponding HLA allotype of the respective subject, with a netMHCPan-4.0 binding rank <0.5. Isotope-labeled synthetic peptides were spiked into a sample matrix of native HLA eluted peptides from a JY cell line at a concentration of 20 fmol/µL, with the purpose of showing spectrum identity between the native and synthetic peptides. The spectral similarity \( \lambda \) was computed analogous to the normalized spectral contrast angle67 between eluted peptide spectra and synthetic isotope labeled peptide spectra:
\[
\lambda (S_1, S_2) = 1 - \frac{2 \cos^{-1}(S_1 \cdot S_2)}{\pi}
\]

where the spectra were encoded as intensity vectors \(S_1\) and \(S_2\) based on their theoretical \(b\) and \(y\) fragment ions by using the mzR (V.2.16.2), msdata (V.0.20.0) and protViz (V.0.4) R packages. Intensities of matching \(y\)- and \(b\)-ion pairs as encoded in the intensity vectors were compared, thereby avoiding the necessity to correct for the mass shift caused by the isotope label. Peaks present in at least one of the spectra were considered for the cross product \((S_1 \cdot S_2)\). Intensities of peaks missing in one spectrum when compared with another were set to zero.

A set of 1000 randomly selected pairwise comparisons was employed to create a reference negative distribution of the spectral similarity score.

**Data storage and web interface**

Data were stored and managed using the biomedical data-management platform qPortal.\(^{28}\) HLA-I and HLA-II peptides were complemented with their tissue and HLA allotype association and stored in an SQL database. A public web server was implemented that allows users to formulate queries against the database, visualize results and allows data export for further analysis. The web front-end was implemented in HTML, CSS and JavaScript based on the front-end framework Bootstrap V.4. The table plugin DataTables was used to provide rapid browsing and filtering for tabular data. Interactive plots were designed using Bokeh and ApexCharts.

**Author affiliations**

1Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany
2Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany
3Applied Bioinformatics, Department of Computer Science, University of Tübingen, Tübingen, Germany
4DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen, Germany
5Department of Obstetrics and Gynecology, University Hospital of Tübingen, Tübingen, Germany
6Neuroimmunology and MS Research, Neurology Clinic, University Hospital Zurich, University of Zurich, Zurich, Switzerland
7Pediatric Stem Cell Transplantation, University Children’s Hospital Zurich, Zurich, Switzerland
8Clinical Neuroscience Center and Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany
9Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tübingen, Germany
10Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany
11Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Zurich, Switzerland
12Clinical Neuroscience Center and Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
13Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, Tübingen, Germany
14Department of Clinical Pharmacology, University of Hospital Tübingen, Tübingen, Germany
15Institute for Virology and Immunobiology, Julius-Maximilians-University Würzburg, Würzburg, Bayern, Germany
16Rudolf Virchow Center - Center for Integrative and Translational Bioimaging, Julius-Maximilians-University Würzburg, Würzburg, Germany
17Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany
18Quantitative Biology Center (QBIC), University of Tübingen, Tübingen, Germany
19Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany
20Cluster of Excellence Machine Learning in the Sciences (EXC 2064), University of Tübingen, Tübingen, Germany
21Institute for Translational Bioinformatics, University Hospital Tübingen, Tübingen, Germany
22Department of Neurosurgery, Cantonal Hospital St.Gallen, St.Gallen, Switzerland
23Neuroscience Center Zurich (ZN2), University of Zurich and ETH Zurich, Zurich, Switzerland

**Contributors**

Conceptualization: AM, LK, LBI, MCN, DJK, LKA, MWL Methodology: LBI, LK, AM, DJK, LBA Software: LBI, LK, ASz, FE, ASz-Validation: AM, LK, LBI, LKF Formal Analysis: LBI, LK, AM, ASC, FE, ASz- LKF Investigation: AM, LKF, LM Resources: MCN, H-GR, SS, OK, MW, LR, HM, RM, SM, TE, PW, MWL, JW, MH-H Data Curation: LK, AM, LBI, MCN, JV, KS, KK-Writing – Original Draft: AM, LK, LBI-Writing & Editing: AM, LK, LBI, MCN, MWL, LKF, ML, OK, SS, H-GR, LR, HM, RM, SM, TE, PW, KK, JSW, JV, MS, LKA, DJK, LM, JW, MH-H Visualization: LBI, LK, AM-Funding Acquisition: H-GR, SS, OK, JSW, MWL

**Funding**

This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy - EXC 2180 – 390900677; the Deutsche Forschungsgemeinschaft (DFG) SFB 865 "Immunotherapy: Molecular Basis and Clinical Application"; the ERC AdG 339842 MUTAEDTING; the Boehringer Ingelheim Foundation for Basic Research in Medicine, the Bosch Research Foundation, and Deutsche Forschungsgemeinschaft (DFG) as part of the German Network for Bioinformatics Infrastructure (de.NBI - FKZ: 31A535A).

**Competing interests**

LB, DJK, ML and LKF are employees of immatics Biotechnologies. LB, DJK, MWL and SS are inventors of patents owned by immatics Biotechnologies. MWL has acted as a paid consultant in cancer immunology for Boehringer Ingelheim Pharma & Co. KG. H-GR is shareholder of immatics Biotechnologies and Curevac AG.

**Patient consent for publication**

Not required.

**Ethics approval**

Human tissue samples were obtained post-mortem during autopsy performed for medical reasons at the University Hospital Zürich. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (BASET-Nr. Req-2016-00604). For none of the included patients a refusal of post-mortem contribution to medical research was documented and study procedures are in accordance with applicable Swiss law for research on humans (Bundesgesetz über die Forschung am Menschen, Art. 38). In addition, the study protocol was reviewed by the ethics committee at the University of Tübingen and received a favorable assessment without any objections to the study conduct (Project Nr. 364/2017B02). Thymus samples were obtained from the University Children’s Hospital Zürich/Switzerland. Thymus tissue was removed during heart surgery for other medical reasons. Tissue samples from residual material not required for diagnostic or other medical purposes were obtained after informed consent from the parents of the respective children, in accordance with the principles of the Declaration of Helsinki. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (EC-Nr. 2014–0699, PB_2017–00631) on February 27th, 2015. Furthermore, two benign ovarian tissue samples were collected for research on humans (OVA-DN278 and OVA-DN281). The study was approved by the ethical committee at the University of Tübingen (Project Number 354/2011BO2). Finally, three primary glioblastoma tumor samples were included. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (EC-Nr. 2014–0699, PB_2017–00631).

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as online supplemental information. All processed data are available in the webserver at: https://hla-ligand-atlas.org/welcome. The LC-MS/MS immunopeptidomics data comprised in the HLA Ligand Atlas has been deposited to the ProteomeXchange.

**Acknowledgements**

We thank Claudia Falkenburger, Ulrich Wulle, Patricia Hrstic, Nicole Bauer and Beate Pimmelr for excellent technical support. We also thank Dogukan Yasar, Tobias Kaster and Jens Bauer for experimental help with the immunopeptidomics experiments. We thank Tjeerd Dijskstra, Etienne Caron, Andreas Friedrich, Carolina Barra, Morten Nielsen and Hannes Röst for valuable discussions.

**Competing interests**

LB, DJK, ML and LKF are employees of immatics Biotechnologies. LB, DJK, MWL and SS are inventors of patents owned by immatics Biotechnologies. MWL has acted as a paid consultant in cancer immunology for Boehringer Ingelheim Pharma & Co. KG. H-GR is shareholder of immatics Biotechnologies and Curevac AG.

**Patient consent for publication**

Not required.

**Ethics approval**

Human tissue samples were obtained post-mortem during autopsy performed for medical reasons at the University Hospital Zürich. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (BASET-Nr. Req-2016-00604). For none of the included patients a refusal of post-mortem contribution to medical research was documented and study procedures are in accordance with applicable Swiss law for research on humans (Bundesgesetz über die Forschung am Menschen, Art. 38). In addition, the study protocol was reviewed by the ethics committee at the University of Tübingen and received a favorable assessment without any objections to the study conduct (Project Nr. 364/2017B02). Thymus samples were obtained from the University Children’s Hospital Zürich/Switzerland. Thymus tissue was removed during heart surgery for other medical reasons. Tissue samples from residual material not required for diagnostic or other medical purposes were obtained after informed consent from the parents of the respective children, in accordance with the principles of the Declaration of Helsinki. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (EC-Nr. 2014–0699, PB_2017–00631) on February 27th, 2015. Furthermore, two benign ovarian tissue samples were collected for research on humans (OVA-DN278 and OVA-DN281). The study was approved by the ethical committee at the University of Tübingen (Project Number 354/2011BO2). Finally, three primary glioblastoma tumor samples were included. The study was approved by the Cantonal Ethics Committee Zürich (KEK) (EC-Nr. 2014–0699, PB_2017–00631).

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as online supplemental information. All processed data are available in the webserver at: https://hla-ligand-atlas.org/welcome. The LC-MS/MS immunopeptidomics data comprised in the HLA Ligand Atlas has been deposited to the ProteomeXchange
deconvolution of mass spectrometry MHC eluted ligand data. J Proteome Res 2020;19:2304–15.

19 Calis JJ, Maybeno M, Greenbaum JA, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013;9:e1003266.

20 Hill N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019;565:240–5.

21 Freudemann LK, Marcu A, Stevanovic S. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology 2018;154:331–45.

22 Löfler MW, Mohr C, Bichmann L, et al. Multi-Omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med 2019;11:28.

23 Basanni-Stemberg M, Bräunlein E, Klar R, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016;7:13404.

24 Chong C, Müller M, Pak H, et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat Commun 2020;11:1293.

25 Laumont CM, Vincent K, Hersand L, et al. Noncooking regions are the main source of targetable tumor-specific antigens. Sci Transl Med 2018;10:eaau5516.

26 Aran D, Camarda R, Odegaard J, et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun 2017;8:1077.

27 Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE-A3-directed T-cells. Sci Transl Med 2015;3:197ra103.

28 Linette GP, Stadtmueller EA, Maus MV, et al. Cardiovascular toxicity and T-cell cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122:863–71.

29 Bichmann L, Neida A, Ghosh M, et al. MHCquant: automated and reproducible data analysis for Immunopeptidomics. J Proteome Res 2019;18:3876–84.

30 Shao W, Pedrioli PGA, Wolski W, et al. The SystemMHC atlas project. Nucleic Acids Res 2018;46:D1237–47.

31 Vita R, Overton JA, Greenbaum JA, et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015;43:D405–12.

32 Boegel S, Löwer M, Bukur T, et al. HLA and proteasome expression profile in body NAP BMC Med Genomics 2018;11:36.

33 Ishii N, Chiba M, Izuka M, et al. Expression of MHC class II antigens (HLA-DR, -DP, and -DQ) on human gastric epithelium. Gastroenterol Jpn 1992;27:23–8.

34 Jiang L, Wang M, Lin S. A quantitative proteome map of the human body. Cell 2020;183:269–83.

35 Wang D, Eraslan B, Wieland T, et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol Syst Biol 2019;15:e8503.

36 Ouuppenskaia T, Law T, Clauer KR. Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer. bioRxiv 2020.

37 Erhard F, Döllen L, Schilling B, et al. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol Immunother 2020;8:1018–26.

38 Almeida LG, Sakabe NJ, de Oliveira AR, et al. CTDdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009;37:DB819–6.

39 Wang C, Gu Y, Zhang K, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nat Commun 2016;7:10499.

40 Müller M, Gfeller D, Coukos G, et al. ‘Hotspots’ of antigen presentation revealed by human leukocyte antigen Ligandomics for neoantigen prioritization. Front Immunol 2017;8:1367.

41 Álvaro-Benito M, Morrison E, Abualrub ET, et al. Quantification of HLA-DM-Dependent major histocompatibility complex class II immunopeptidomes by the peptide landscape antigenic epitope utility front. Front Immunol 2018;9:872.

42 Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217–21.

43 Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222–6.

44 Szolek A, Schubert B, Mohr C, et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 2014;30:3101–6.

45 Barnstable CJ, Bodmer WF, Brown G, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978;14:9–20.

46 Scolman JM, Hibbin J, Kearney L, et al. HLA-Dr monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukemia myeloid progenitor cells. Br J Haematol 1982;52:411–20.
47 Pawelec G, Ziegler A, Wernet P. Dissection of human allostimulatory determinants with cloned T cells: stimulation inhibition by monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, and 58 against distinct human MHC class II molecules. *Hum Immunol* 1985;12:165–76.

48 Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. *Curr Opin Immunol* 1995;7:85–96.

49 Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. *Nature* 1994;368:215–21.

50 Lippolis JD, White FM, Marto JA, et al. Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. *J Immunol* 2002;169:5089–97.

51 Perez-Riverol Y, Csordas A, Bai J, et al. The pride database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res* 2019;47:D442–50.

52 Ewels PA, Peltzer A, Fillinger S, et al. The rf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol* 2020;38:276–8.

53 Röst HL, Sachsenberg T, Aiche S, et al. OpenMS: a flexible open-source software platform for mass spectrometry data analysis. *Nat Methods* 2016;13:741–8.

54 Eng JK, Hoopmann MR, Jahan TA, et al. A deeper look into Comet—a implementation and features. *J Am Soc Mass Spectrom* 2015;26:1865–74.

55 The M, MacCoss MJ, Noble WS, et al. Fast and accurate protein false discovery rates on large-scale proteomics data sets with percolator 3.0. *J Am Soc Mass Spectrom* 2016;27:1719–27.

56 Savitski MM, Wilhelm M, Hahne H, et al. A scalable approach for protein false discovery rate estimation in large proteomic data sets. *Mol Cell Proteomics* 2015;14:2394–404.

57 Reiter L, Claassen M, Schrimpf SP, et al. Protein identification false discovery rates for very large proteomics data sets generated by tandem mass spectrometry. *Mol Cell Proteomics* 2009;8:2405–17.

58 Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics* 1999;50:213–9.

59 Jurtz V, Paul S, Andreatta M, et al. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. *J Immunol* 2017;199:3360–8.

60 Di Marco M, Schuster H, Backert L, et al. Unveiling the peptide motifs of HLA-A and HLA-G from naturally presented peptides and generation of binding prediction matrices. *J Immunol* 2017;199:2639–51.

61 Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat Protoc* 2016;11:2301–19.

62 Weisser H, Choudhary JS. Targeted feature detection for Data-Dependent shotgun proteomics. *J Proteome Res* 2017;16:2964–74.

63 Mi H, Muruganujan A, Ebert D, et al. Panther version 14: more genomes, a new Panther GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res* 2019;47:D419–26.

64 Tran NH, Qiao R, Xin L, et al. Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry. *Nat Methods* 2019;16:63–6.

65 Zhang J, Xin L, Shan B, et al. Peaks DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. *Mol Cell Proteomics* 2012;11:M111.010587.

66 Pfeifer N, Leinenbach A, Huber CG, et al. Statistical learning of peptide retention behavior in chromatographic separations: a new kernel-based approach for computational proteomics. *BMC Bioinformatics* 2007;8:468.

67 Toprak UH, Gillet LC, Maiolica A, et al. Conserved peptide fragmentation as a benchmarking tool for mass spectrometers and a discriminating feature for targeted proteomics. *Mol Cell Proteomics* 2014;13:2056–71.

68 Mohr C, Friedrich A, Wojnar D, et al. qPortal: a platform for data-driven biomedical research. *PLoS One* 2018;13:e0191803.
The HLA Ligand Atlas: A benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

Ana Marcu§, Leon Bichmann§, Leon Kuchenbecker§, Daniel Johannes Kowalewski, Lena Katharina Freudenmann, Linus Backert, Lena Mühlenbruch, András Szolek, Maren Lübke, Philipp Wagner, Tobias Engler, Sabine Matovina, Jian Wang, Mathias Hauri-Hohl, Roland Martin, Konstantina Kapolou, Juliane Sarah Walz, Julia Velz, Holger Moch, Luca Regli, Manuela Silginer, Michael Weller, Markus W. Löffler, Florian Erhard, Andreas Schlosser, Oliver Kohlbacher, Stefan Stevanović, Hans-Georg Rammensee, Marian Christoph Neidert

§these authors contributed equally to this work

Supplementary FIGURES
A QUALITY CONTROL WORKFLOW

**HLA-I binding prediction**

SYFPEITHI:
- $s_{tr} \geq 0.5$
- or
- NetMHCpan 4.1b:
  - $s_{net} \leq 2.0$

**Percentage of HLA-I binders per sample**

\( \geq 50\% \)

**Length distribution**

Mode = 9

**All samples**

sample = tissue + donor
3 MS runs per sample
1% peptide-level FDR

**HLA-II binding prediction**

SYFPEITHI:
- $s_{tr} \geq 0.5$
- or
- MHC2Pred 1.1:
  - $s_{net} \leq 5.0$
- or
- NetMHCIIpan 4.0:
  - $s_{net} \leq 5.0$

**Percentage of HLA-II binders per sample**

\( \geq 10\% \)

**Length distribution**

12 \( \leq \) Mode \( \leq 18 \)

B OUTLIER REMOVAL AND TOTAL CONTENT OF THE HLA LIGAND ATLAS

**Density**

% HLA-I binders per MS run

n = 624

% HLA-II binders per MS run

n = 678

**Mode of length distribution**

n = 663

n = 13

**Density**

% HLA-I peptides per MS run

n = 651

n = 27

**Mode of length distribution**

HLA Ligand Atlas contains:

198 HLA-I samples

(623 MS runs)

HLA Ligand Atlas contains:

220 HLA-II samples

(651 MS runs)
Supplementary Figure S1: Computational workflow and quality control thresholds (related to Figure 1)

(A) Data from three LC-MS/MS runs (technical replicates) per sample (one tissue from one subject) were processed with MHCquant with a local peptide-level FDR of 1%. Identified peptides were categorized into peptides predicted as strong, weak, or non-binders. HLA-I peptides were predicted by SYFPEITHI and NetMHCpan 4.0, employing a cut-off threshold of $s_{\text{SYF}} \geq 0.5$ and $s_{\text{rank}} \leq 2.0$, respectively. HLA-II peptides were predicted with MixMHCpred, NetMHCIIpan 4.0 and SYFPEITHI with equal thresholds. Samples with less than 50% and 10% predicted binders per technical replicate for HLA-I and HLA-II immunopeptidomes were excluded from further analysis and are not included in the HLA Ligand Atlas database release. Finally, we employed a stringent cut-off concerning the mode of the peptide length distribution for HLA-I (mode equal to 9) and -II (mode between 12 to 18) immunopeptidomes.

(B) LC-MS/MS runs not pertaining to the aforementioned QC thresholds (dashed red lines) concerning the percentage of predicted HLA-binders and the peptide length distribution were not included in the HLA Ligand Atlas database release. Violin plots (left) depict the percentage of peptides predicted to be HLA-binders per LC-MS/MS run and the quality control cut-off for LC-MS/MS runs employed for HLA-I and -II immunopeptidomes. Dot plots (center) depict the mode of the peptide length distribution encountered per LC-MS/MS run and the quality control cut-off employed for HLA-I and -II. The number of LC-MS/MS runs (HLA-I - blue and HLA-II orange) failing the QC thresholds is indicated by red dots. The final number of LC-MS/MS runs and samples selected for inclusion into the HLA Ligand Atlas database release and data analysis are indicated on the right and differ for HLA-I and -II experiments.
Supplementary Figure S2: Time-Series Experiment (related to Figure 1)

The time series experiment was carried out on three biological samples from three subjects. Bar plots (left hand side) indicate the number of identified HLA-I predicted binders (blue) and predicted non-binders (grey) across technical replicates and timepoints for each timeseries. Time series (right hand side) indicate individual clusters (K-Means using four seeds) of trajectories of quantified MS1 intensity across technical replicates and timepoints. Intermediate trend lines for each cluster are indicated in blue and the percentage of trajectories populating a given cluster is annotated at the top edge of each plot. The trajectories of all timepoints were set in relation to the initial timepoint. The analysis reveals that the number of identified peptides and their percentage of predicted HLA-binders is constant and that most trajectories do not vary much across time points.
Supplementary Figure S3: Position-wise proteome coverage (related to Figure 1C, Figure 2B and C)

(A-B) Analysis of the different propensities of HLA-I (blue) and –II (orange), allotypes concerning the presentation of peptides. In turn different percentages of the source proteome are position-wise covered. For example, HLA-B*15:01 ligands cover over 1% of the HLA-I source proteome (see Figure 2B, C).

(C) Global analysis of the position-wise coverage of all proteins presented on either HLA-I (blue), HLA-II (orange), or both independent of specific allotypes (see Figure 1C).
A. Number of HLA-I peptides per donor

| Tissue       | AUT | DN1 | DN2 | DN3 | DN4 | DN5 | DN6 | OVA |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Myelon       |     |     |     |     |     |     |     |     |
| Skin         |     |     |     |     |     |     |     |     |
| Brain        |     |     |     |     |     |     |     |     |
| Muscle       |     |     |     |     |     |     |     |     |
| Heart        |     |     |     |     |     |     |     |     |
| Testis       |     |     |     |     |     |     |     |     |
| Aorta        |     |     |     |     |     |     |     |     |
| Gallbladder  |     |     |     |     |     |     |     |     |
| Prostate     |     |     |     |     |     |     |     |     |
| Bladder      |     |     |     |     |     |     |     |     |
| Ovary        |     |     |     |     |     |     |     |     |
| Cerebellum   |     |     |     |     |     |     |     |     |
| Thyroid      |     |     |     |     |     |     |     |     |
| Colon        |     |     |     |     |     |     |     |     |
| Mamma        |     |     |     |     |     |     |     |     |
| Esophagus    |     |     |     |     |     |     |     |     |
| Trachea      |     |     |     |     |     |     |     |     |
| Small intestine |   |     |     |     |     |     |     |     |
| Pancreas     |     |     |     |     |     |     |     |     |
| Adrenal gland|     |     |     |     |     |     |     |     |
| Kidney       |     |     |     |     |     |     |     |     |
| Lymph node   |     |     |     |     |     |     |     |     |
| Uterus       |     |     |     |     |     |     |     |     |
| Bone marrow  |     |     |     |     |     |     |     |     |
| Spleen       |     |     |     |     |     |     |     |     |
| Lung         |     |     |     |     |     |     |     |     |
| Thymus       |     |     |     |     |     |     |     |     |

B. Number of HLA-II peptides per donor

| Tissue       | AUT | DN1 | DN2 | DN3 | DN4 | DN5 | DN6 | OVA |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Myelon       |     |     |     |     |     |     |     |     |
| Skin         |     |     |     |     |     |     |     |     |
| Brain        |     |     |     |     |     |     |     |     |
| Muscle       |     |     |     |     |     |     |     |     |
| Heart        |     |     |     |     |     |     |     |     |
| Testis       |     |     |     |     |     |     |     |     |
| Aorta        |     |     |     |     |     |     |     |     |
| Gallbladder  |     |     |     |     |     |     |     |     |
| Prostate     |     |     |     |     |     |     |     |     |
| Bladder      |     |     |     |     |     |     |     |     |
| Ovary        |     |     |     |     |     |     |     |     |
| Cerebellum   |     |     |     |     |     |     |     |     |
| Thyroid      |     |     |     |     |     |     |     |     |
| Colon        |     |     |     |     |     |     |     |     |
| Mamma        |     |     |     |     |     |     |     |     |
| Esophagus    |     |     |     |     |     |     |     |     |
| Trachea      |     |     |     |     |     |     |     |     |
| Small intestine |   |     |     |     |     |     |     |     |
| Pancreas     |     |     |     |     |     |     |     |     |
| Adrenal gland|     |     |     |     |     |     |     |     |
| Kidney       |     |     |     |     |     |     |     |     |
| Lymph node   |     |     |     |     |     |     |     |     |
| Uterus       |     |     |     |     |     |     |     |     |
| Bone marrow  |     |     |     |     |     |     |     |     |
| Spleen       |     |     |     |     |     |     |     |     |
| Lung         |     |     |     |     |     |     |     |     |
| Thymus       |     |     |     |     |     |     |     |     |

C. Hierarchical clustering of samples based on peptide Jaccard similarity

D. Distribution of pairwise peptide Jaccard similarities
Supplementary Figure S4: Distribution of peptide identifications and yields across tissues and subjects and peptide-based hierarchical sample clustering (related to Figure 2D, E, and Figure 4A)

(A-B) HLA-I peptide yields per tissue and subject are illustrated in a heatmap for HLA-I and II. The color range is in accordance with the number of peptides identified in each sample as indicated in the legend on the right (HLA-I – blue, HLA-II – orange).

(C) Pairwise hierarchical clustering of samples based on the Jaccard similarity between HLA-I (blue) and HLA-II (orange) peptides. The dendrogram illustrates the nearest neighbor based on the similarity between tissues and subjects. See Figure 2D.

(D) Violin plots illustrate the distribution of the peptide Jaccard similarity index for each pairwise comparison between the same subject - different tissues; different subjects - the same tissue, and different subject - different tissues. Results confirmed for HLA-I and II source proteins Figure 2D and E, respectively.
Supplementary Figure S5: Hierarchical sample clustering for HLA and tissue subset matched sample groups (related to Figure 2D, E)

(A) Hierarchical clustering of predicted HLA-A*02:01 binding peptide sets based on their Jaccard similarity. Samples were selected from donors carrying the HLA-A*02:01 allele and subsequently filtered for predicted binders against that allele. The samples were then divided into subsets of donors and tissues such that every tissue was measured in every donor. The resulting subsets of samples were then clustered as described in the Methods section.

(B) The distributions of Jaccard similarity scores for equivalently HLA allele matched sample pairs over all HLA allotypes present in the dataset.
Supplementary Figure S6: Linear models of gene expression across tissues (related to Figure 3). The correlation of HLA-I and -II peptide yields across tissues was assessed with respect to the expression levels (RPKM) of multiple immune related genes of the HLA-I and -II antigen presentation pathway. (RNA expression values were taken from a different publication (Boegel et al., 2018). (A,C) Symmetrical cross-correlation matrices were generated, illustrating the spearman correlation coefficients (rho) of the number of identified HLA-I and -II ligands with expression levels (RPKM) of relevant genes in the HLA-I and -II antigen presentation pathways and among each other. The color-coded dots and their size represent the degree (Spearman rho) of positive (blue) or negative correlation (red). (B,D) In addition, linear models illustrate HLA-I and -II immunopeptidome yields correlated to log scaled gene expression values (RPKM) of genes involved in the HLA-I and -II antigen processing pathway, respectively. The R2 correlation coefficient is depicted in the top left corner for each comparison.
Supplementary Figure S7: Manual validation of cryptic peptide identifications with isotope labeled synthetic peptides (related to Figure 6). Six exemplary spectral comparisons depict cryptic peptides identified in diverse tissues and subjects (upper spectrum) related to their synthetic isotope labeled counterpart (lower spectrum). The isotope labeled amino acid is highlighted in red and its corresponding label and mass are annotated. Matching b- (red), y-ions (blue) and neutral losses (green) and their corresponding fragment masses are annotated to each peak in the spectra. The spectral similarity score of the given comparison is annotated in the top right.